Biohaven's BHV-1420 reduces disease-driving antibodies by over 90% in mouse study

• Biohaven presented preclinical results for BHV-1420 in membranous nephropathy at ASN Kidney Week on Oct. 24, 2026.
• Laboratory testing showed recognition of most patient autoantibodies; a single injection rapidly reduced circulating disease-driving antibodies in mice.
• The investigational drug targets harmful autoantibodies for liver degradation without broad immunosuppression.
• BHV-1420 becomes the second program in its TRAP kidney disease portfolio, built on technology exclusively licensed from Yale University.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biohaven Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610260730PR_NEWS_USPR_____NE80438) on October 26, 2026, and is solely responsible for the information contained therein.